Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer
Changfa Shu(Central South University), Haian Fu(Emory University), Danielle Cicka(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Yuan Liu(Emory University), Gabriel Sica(Emory University), Xiulei Mo(Emory University), Dacheng Fan(Emory University), Deon B. Doxie(Vanderbilt University), Andrei A. Ivanov, Wei Zhou(Emory University), Alafate Wahafu(First Affiliated Hospital of Xi'an Jiaotong University), Kavita M. Dhodapkar(Emory University), Suresh S. Ramalingam(Emory University), Madhav V. Dhodapkar(Emory University), Qiankun Niu, Jianfeng Li(Emory University), Ruiyang Bai(Central South University), Xi Zheng(Emory University), Sean P. Doyle(Emory University), Yuhong Du(Emory University), Jennifer W. Carlisle(Emory University)
Cited by 7
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899